Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Ortho Tri-Cyclen Lo is an oral contraceptive tablet containing a norgestimate/ethinyl estradiol combination in a triphasic regimen. It is indicated for pregnancy prevention in women of reproductive age. The product works through hormonal suppression of ovulation and modification of cervical mucus.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting reduced team investment and limited growth opportunity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
No linked job opportunities are currently available for this product, reflecting its LOE-approaching status and minimal active commercial expansion. Career roles on Ortho Tri-Cyclen Lo are primarily defensive, focused on maintaining market share and managing generic competition rather than driving growth.
Worked on ORTHO TRI-CYCLEN LO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.